Description
HYALUAL Xela Rederm 2.2% 1x2ml is a sterile injectable skin revitalisation treatment developed by Hyalual Group as part of its Redermalization® product range. The formulation combines non-cross-linked hyaluronic acid with sodium succinate, creating a dual-component approach intended to support skin hydration and improve overall skin quality.
The product contains 22 mg/ml hyaluronic acid (2.2%) and 16 mg/ml sodium succinate. Hyaluronic acid contributes to moisture retention and extracellular matrix support, while sodium succinate is incorporated as part of the manufacturer’s Redermalization® technology, which is associated with cellular metabolic processes and antioxidant activity.
Compared with the lower-strength 1.1% formulation, HYALUAL Xela Rederm 2.2% provides a higher concentration of hyaluronic acid and is commonly positioned for patients presenting with more noticeable signs of skin ageing, reduced elasticity, and dehydration. The product is supplied as a sterile 2 ml syringe and is intended exclusively for administration by qualified medical professionals.
What HYALUAL Xela Rederm 2.2% 1x2ml Is Similar To
HYALUAL Xela Rederm 2.2% belongs to the category of injectable skin boosters and biorevitalisation products intended to improve skin quality rather than restore facial volume. Comparable products include Profhilo®, Sunekos®, Jalupro®, and other injectable skin revitalisation treatments used within aesthetic medicine.
Like Profhilo®, Xela Rederm focuses on hydration and skin quality enhancement rather than volumisation. However, the formulations differ significantly. Profhilo contains stabilised hyaluronic acid complexes, whereas Xela Rederm combines non-cross-linked hyaluronic acid with sodium succinate as part of the manufacturer’s Redermalization® technology.
Compared with Sunekos®, which combines hyaluronic acid with amino acid complexes, Xela Rederm utilises sodium succinate instead of amino acids. Both approaches are designed to support skin quality improvement but rely on different formulation concepts.
This comparison is provided for clinical orientation only and does not imply interchangeability.
Treatment Areas / Indications
According to manufacturer and distributor information, HYALUAL Xela Rederm 2.2% may be used in aesthetic skin revitalisation protocols involving:
- Face
- Neck
- Décolletage
- Hands
Potential indications include:
- Skin dehydration
- Reduced skin elasticity
- Dull skin appearance
- Early to moderate signs of skin ageing
- Skin quality improvement protocols
Treatment planning should be performed by qualified healthcare professionals following patient assessment.
Usage / Administration (IFU-Only Section)
According to available manufacturer documentation:
Injection depth: Superficial dermis.
Volume per injection site: Not provided by manufacturer.
Needle gauge: Not provided by manufacturer in publicly available IFU documentation.
Frequency / Number of sessions: Not provided by manufacturer.
Professional-use disclaimer: HYALUAL Xela Rederm 2.2% should be administered only by qualified healthcare professionals trained in aesthetic injection procedures and aseptic technique.
Some practitioners may apply individual injection protocols or customised treatment schedules; these methods are not included in the manufacturer’s publicly available IFU and should not be considered official guidance.
Ingredient List
Active Ingredients
- Non-cross-linked hyaluronic acid – 22 mg/ml (2.2%)
- Sodium succinate – 16 mg/ml
Excipients
- Phosphate buffer solution
- Water for injection
Hyaluronic Acid Concentration
- 22 mg/ml (2.2%)
Presentation & Longevity
Presentation
- 1 × 2 ml sterile prefilled syringe
- Single-use injectable product
- Professional-use packaging
Longevity
Treatment duration and persistence are not specifically stated by the manufacturer. Clinical outcomes may vary depending on patient characteristics, treatment objectives, skin condition, and practitioner technique.
Any longevity estimates referenced in clinical practice should not be interpreted as manufacturer-guaranteed results.
Safety Notes / Contraindications
According to manufacturer guidance and standard injectable treatment precautions:
- Contraindicated in patients with hypersensitivity to hyaluronic acid, sodium succinate, or any formulation component.
- Should not be administered into areas affected by active infection, inflammation, or skin disease.
- Not intended for intravascular administration.
- Must be administered by appropriately trained healthcare professionals.
Patients should undergo a comprehensive medical consultation before treatment to determine suitability.
Regulatory Status
Manufacturer: Hyalual Group.
Regulatory Status: CE-marked medical device according to manufacturer and authorised distributor documentation.
Users should verify current registration status, local regulatory compliance, and market-specific approvals through official documentation and regulatory databases.
FAQ
1. What is HYALUAL Xela Rederm 2.2% used for?
HYALUAL Xela Rederm 2.2% is an injectable skin revitalisation treatment designed to support hydration and improve overall skin quality. The product combines non-cross-linked hyaluronic acid and sodium succinate and is commonly incorporated into aesthetic protocols addressing skin ageing, dehydration, and reduced elasticity.
2. How does Xela Rederm 2.2% differ from Xela Rederm 1.1%?
The primary difference is the hyaluronic acid concentration. Xela Rederm 2.2% contains 22 mg/ml hyaluronic acid, while Xela Rederm 1.1% contains 11 mg/ml. Both products contain sodium succinate and belong to the Redermalization® range, but the 2.2% formulation provides a higher concentration of hyaluronic acid.
3. What role does sodium succinate play in the formulation?
According to manufacturer information, sodium succinate forms part of the Redermalization® concept and is included alongside hyaluronic acid. Succinate participates in cellular metabolic pathways and represents one of the distinguishing features of the Xela Rederm range compared with many conventional skin boosters.
4. Is HYALUAL Xela Rederm 2.2% a dermal filler?
No. Although it contains hyaluronic acid, Xela Rederm 2.2% is generally classified within the skin booster and skin revitalisation category rather than the volumising dermal filler category. Its primary purpose is skin quality improvement rather than contour restoration.
5. Does HYALUAL Xela Rederm 2.2% contain lidocaine?
No. Available manufacturer and distributor information indicates that HYALUAL Xela Rederm 2.2% does not contain lidocaine. Practitioners should always verify formulation details using the latest IFU and product packaging before administration.
